Mirae Asset Global Investments Co. Ltd. Has $805,000 Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

Mirae Asset Global Investments Co. Ltd. grew its position in Sana Biotechnology, Inc. (NASDAQ:SANA) by 286.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 197,386 shares of the company’s stock after buying an additional 146,303 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Sana Biotechnology were worth $805,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of SANA. TD Asset Management Inc raised its holdings in Sana Biotechnology by 100.0% during the third quarter. TD Asset Management Inc now owns 362,652 shares of the company’s stock worth $1,403,000 after acquiring an additional 181,326 shares in the last quarter. State of Michigan Retirement System bought a new stake in Sana Biotechnology during the third quarter worth about $2,663,000. Principal Financial Group Inc. raised its holdings in Sana Biotechnology by 13.1% during the third quarter. Principal Financial Group Inc. now owns 42,664 shares of the company’s stock worth $165,000 after acquiring an additional 4,928 shares in the last quarter. Jump Financial LLC bought a new stake in Sana Biotechnology during the third quarter worth about $52,000. Finally, Barclays PLC raised its holdings in Sana Biotechnology by 3.1% during the third quarter. Barclays PLC now owns 205,567 shares of the company’s stock worth $797,000 after acquiring an additional 6,096 shares in the last quarter. 88.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Sana Biotechnology

In other news, Director Robert Nelsen bought 1,818,181 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were bought at an average price of $5.50 per share, with a total value of $9,999,995.50. Following the completion of the transaction, the director now owns 12,446,022 shares of the company’s stock, valued at $68,453,121. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 34.90% of the company’s stock.

Sana Biotechnology Stock Up 6.1 %

NASDAQ:SANA opened at $8.58 on Thursday. The stock’s 50 day moving average price is $9.07 and its two-hundred day moving average price is $6.05. The firm has a market capitalization of $1.89 billion, a price-to-earnings ratio of -5.84 and a beta of 1.61. Sana Biotechnology, Inc. has a 12-month low of $2.74 and a 12-month high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.03. During the same period in the prior year, the business posted ($0.40) earnings per share. Equities research analysts expect that Sana Biotechnology, Inc. will post -1.02 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on SANA shares. JMP Securities upped their target price on Sana Biotechnology from $8.00 to $15.00 and gave the stock a “market outperform” rating in a report on Friday, March 1st. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Sana Biotechnology in a report on Friday, March 1st.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.